By proceeding, you agree to our Terms of Use and Privacy Policy.
2021 was a landmark year for clinical readouts within the oncolytic virotherapy field, and now OV developers are poised and ready at the cusp of something remarkable and this promising therapeutic is set to be a critical modality within cancer immunotherapy.
Get clinical guidance on oncolytic virotherapy.
Learn from case study presentations, workshops, and conversations on oncolytic virotherapy selection and combination therapy considerations.
Discover interactive discussions on optimizing OV therapeutics to reach patient safety effectively and rapidly.
Hear from Antonio Chiocca, Austin Nuschke, Barbara Haertl, and others on oncolytic virotherapy.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
Analytical scientists and clinical researchers worldwide rely on Agilent to help fulfill their most complex laboratory demands.
For over 25 years, FUJIFILM Diosynth Biotechnology’s mission has been advancing tomorrow’s medicine.
Make faster and better informed drug development decisions In partnership with the world’s leading drug development experts to help you keep up with the pace of preclinical and clinical research developments.
Batavia Biosciences is a science-based CDMO that offers personalized services that fully support all the stages of biopharmaceutical development, from cloning to GMP manufacture and release of clinical material for phase I/II studies.
OBiO Technology (Shanghai) Corp., Ltd. ('OBiO', SSE:688238.SH) is a gene and cell therapy-focused biotechnology company founded in 2013.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.